Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) EBITDA Margin (2024)

Zentalis Pharmaceuticals has reported EBITDA Margin over the past 1 years, most recently at 185.55% for Q4 2024.

  • For Q4 2024, EBITDA Margin changed N/A year-over-year to 185.55%; the TTM value through Sep 2025 reached 615.16%, down 9922.0%, while the annual FY2024 figure was 283.57%, N/A changed from the prior year.
  • EBITDA Margin for Q4 2024 was 185.55% at Zentalis Pharmaceuticals, down from 61.06% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 61.06% in Q1 2024 and troughed at 185.55% in Q4 2024.